Company Overview - Jinhai Medical Technology Co., Ltd. (stock code: 02225.HK) operates primarily in the service provider sector, offering labor dispatch and supporting services to construction contractors in Singapore, along with dormitory, IT, and construction support services [2] - The company aims to leverage its advantages in Hong Kong and Singapore to expand its existing business, enter new industries, and seek investment cooperation opportunities to enhance long-term returns for shareholders [2] Financial Performance - As of December 31, 2024, Jinhai Medical reported total revenue of 267 million yuan, representing a year-on-year growth of 10.07% [1] - The company recorded a net profit attributable to shareholders of -95.599 million yuan, a significant decrease of 471.95% compared to the previous year [1] - The gross profit margin stood at 22.84%, while the debt-to-asset ratio was 44.32% [1] Market Performance - On July 17, the Hang Seng Index closed down 0.08% at 24,498.95 points, while Jinhai Medical's stock price increased by 11.52% to 1.84 HKD per share, with a trading volume of 4.035 million shares and a turnover of 7.2649 million HKD [1] - Over the past month, Jinhai Medical's stock has seen a cumulative increase of 20.44%, but it has declined by 13.16% year-to-date, underperforming the Hang Seng Index by 22.22% [1] Valuation Metrics - Currently, there are no institutional investment ratings for Jinhai Medical [2] - The average price-to-earnings (P/E) ratio for the support services industry (TTM) is 3.73, with a median of 3.77 [2] - Jinhai Medical's P/E ratio is -82.63, ranking 57th in the industry, compared to other companies in the Chinese education sector with P/E ratios ranging from 1.47 to 2.8 [2] Corporate Actions - On July 13, 2025, the company plans to issue 120 million new shares, representing 2.27% of the enlarged share capital, at a subscription price of 1.35 HKD per share, which is a 17.68% discount to the previous closing price [3]
今海医疗科技（02225.HK）7月17日收盘上涨11.52%，成交726.49万港元